Cyclerion Therapeutics, Inc. 8-K

What Happened

• On April 1, 2026 Cyclerion Therapeutics, Inc. (Cyclerion) and Korsana Biosciences, Inc. entered into an Agreement and Plan of Merger under which Cyclerion will acquire Korsana through a two-step merger (First Merger into Korsana; Second Merger into a Cyclerion subsidiary). The transaction is intended to qualify as a tax-free reorganization under Section 368(a).
• The parties expect the combined company to be led by Korsana’s president & CEO and the Cyclerion board at the Effective Time to consist of six members designated by Korsana. The transaction is expected to close in Q3 2026, subject to shareholder approvals and customary conditions (including SEC S-4 effectiveness, Nasdaq listing approval and HSR clearance).

Key Details

• Date filed: April 1, 2026; expected close: third quarter 2026 (subject to approvals).
• Ownership pro forma at closing (before the financing closes): pre‑Merger Korsana holders ~1.5% and pre‑Merger Cyclerion shareholders ~98.5% of the combined company.
• Concurrent financing: institutional and accredited investors committed to purchase PIPE securities for approximately $380 million to close immediately prior to the Merger; closing is subject to Merger conditions and required Korsana stockholder approval. (The Merger also conditions closing on a securities purchase agreement providing for receipt of at least $150 million.)
• Governance & equity changes: Cyclerion will seek shareholder approval to amend its charter (including changing its name to Korsana Biosciences, effect a reverse split, increase authorized shares, redomicile and create a new Series B Non‑Voting Convertible Preferred Stock). Series B shares convert into 1,000 common shares (subject to conversion caps) and carry protections including the right to elect four directors while at least 30% remain outstanding.
• Shareholder protections and mechanics: Cyclerion will issue one contingent value right (CVR) per pre‑Merger Cyclerion share to capture potential proceeds from disposition of certain legacy assets (with defined payout windows and no guaranteed payment). Key insiders have entered support agreements and certain Korsana and Cyclerion holders agreed to lock-ups and voting support (Korsana holders ~43.9%; Cyclerion directors/officers ~24.2%).

Why It Matters

• This is a change‑of‑control deal that will place Korsana’s management and board in control of the combined company and could materially change strategy, leadership and governance for Cyclerion shareholders.
• The planned ~$380M PIPE (and minimum financing condition) is material to the combined company’s cash runway; closing is contingent on that financing and multiple shareholder and regulatory approvals.
• Pre‑Merger Cyclerion shareholders receive CVRs tied to Cyclerion legacy asset proceeds (not immediate cash), while Series B Preferred issued to Korsana investors carries conversion rights, governance protections and potential dilution mechanics investors should note.
• Investors should watch upcoming proxy materials (Form S-4), shareholder votes, Nasdaq listing approval and the financing close for timing and potential effects on share count, control and valuation.